PSMA PET改善转移性前列腺癌患者硬脑膜为基础颅内病变的表征
回顾性分析26例前列腺癌患者44个颅内病变(7个脑膜瘤、37个硬脑膜转移瘤),比较PSMA PET的SUVmax与以腮腺为参照的SUVR。脑膜瘤SUVmax和SUVR均显著低于转移瘤,SUVR的AUC为0.903,最佳截断值0.81,敏感度81.1%、特异度100%。PSMA PET有潜力鉴别脑膜瘤与硬脑膜转移瘤。
要点
- 脑膜瘤SUVmax中位2.7、SUVR中位0.26,均显著低于硬脑膜转移瘤的11.5和1.05。
- 以腮腺为参照的SUVR鉴别脑膜瘤与硬脑膜转移瘤AUC为0.903,最佳截断值0.81。
- SUVR截断值0.81时敏感度81.1%、特异度100%,特异度高有助于排除脑膜瘤。
核心结论
- PSMA PET有潜力鉴别前列腺癌患者的脑膜瘤与硬脑膜转移瘤,可能优化临床管理并改善患者结局。
研究设计与样本
- 回顾性分析前列腺癌合并颅内病变患者的PSMA PET/CT扫描,共纳入26例男性患者(中位年龄76.5岁,范围59-96岁),分析44个病变(7个脑膜瘤、37个转移瘤);病变分类依据MRI特征、纵向随访及组织病理学特征。
关键影像表现/征象
- 脑膜瘤的SUVmax中位2.7,硬脑膜转移瘤SUVmax中位11.5,脑膜瘤显著低于转移瘤(p=0.001)。
- 脑膜瘤的SUVR中位0.26,硬脑膜转移瘤SUVR中位1.05,脑膜瘤显著低于转移瘤(p<0.001)。
- SUVR以腮腺为参照计算,ROC分析AUC为0.903。
诊断标准与关键数值
- SUVR鉴别脑膜瘤与硬脑膜转移瘤的最佳截断值为0.81,敏感度81.1%、特异度100%。
- 病变分类以MRI特征、纵向随访及组织病理学特征为参考标准。
临床应用与阅片要点
- 对前列腺癌患者的硬脑膜为基础颅内病变,可测量PSMA PET的SUVmax及以腮腺为参照的SUVR辅助鉴别脑膜瘤与硬脑膜转移瘤。
- SUVR截断值0.81时特异度100%,高于该值提示硬脑膜转移瘤可能,但敏感度81.1%提示阴性不能完全排除转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Theranostic approaches combining prostate-specific membrane antigen (PSMA)-PET/CT or PET/MRI with PSMA-targeted radionuclide therapy have improved clinical outcomes in patients with prostate cancer (PCa) especially metastatic castrate resistant prostate cancer. Dural metastases in PCa are rare but can pose a diagnostic challenge, as meningiomas, a more common dural based lesions have been shown to express PSMA. The aim of this study is to compare PSMA PET parameters between brain lesions classified as dural metastases and meningiomas in prostate cancer patients.
METHODS: A retrospective analysis of PSMA PET/CT scans in patients with PCa and intracranial lesions was conducted. Brain lesions were categorized as dural metastases or meningiomas based on MRI characteristics, longitudinal follow-up, and histopathological characteristics. Standardized uptake values (SUVmax) of each brain lesion were measured, along with SUV ratio referencing parotid gland (SUVR). SUVs between lesions classified as metastases and meningiomas, respectively, were compared using Mann-Whitney-test. Diagnostic accuracy was evaluated using ROC analysis.
RESULTS: 26 male patients (median age: 76.5 years, range: 59-96 years) met inclusion criteria. A total of 44 lesions (7 meningiomas and 37 metastases) were analyzed. Median SUVmax and SUVR were significantly lower in meningiomas compared to metastases (SUVmax: 2.7 vs. 11.5, p = 0.001; SUVR: 0.26 vs. 1.05, p < 0.001). ROC analysis demonstrated AUC 0.903; the optimal cut-off value for SUVR was 0.81 with 81.1 % sensitivity and 100 % specificity.
CONCLUSION: PSMA PET has the potential to differentiate meningiomas from dural-based metastases in patients with PCa, which can optimize clinical management and thus improve patient outcomes.
引用
- Yadav D, Dutruel SP, O'Dwyer E, et al. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer. Eur J Radiol. 2024. PMID: 39226675. doi:10.1016/j.ejrad.2024.111711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。